However, the prognostic significance of PD-L1 in HER2+ BC is still controversial since some studies documented poor outcomes in metastatic HER2+/PD-L1+tumors, whereas other authors documented improved survival in patients with high levels of PD-1/PD-L1 expression [13,55]. This evidence concerns the gene CD274 and breast cancer.